Disease Modification In Crohn’s Disease:
Improving Outcomes Through Early Intervention & New Therapeutic Targets
INTRODUCTION
Crohn’s disease is a chronic inflammatory bowel disorder that poses significant challenges for patients and healthcare providers alike. Early intervention and the identification of new therapeutic targets are crucial for enhancing patient outcomes.
In this engaging session, we bring together leading experts in the field of gastroenterology who will delve into pivotal advancements in the understanding and management of Crohn’s disease. Drawing insights from recent medical congresses, our experts will explore key developments in epidemiology, drivers for early intervention, innovative treatment approaches, and the emerging landscape of therapeutic targets.
BEGIN
Learning Goal
The goal of this activity is to increase healthcare professionals knowledge and competency in evidence-based management strategies for patients with anemia and Crohn's disease.
Target Audience
This activity is intended for HCPs who manage adult patients with Crohn’s disease, including Physicians/General Practitioners, Surgeons, Advanced Practice Providers (Nurse Practitioners and Physician Assistants/Associates), Nurses, and allied healthcare professionals practicing globally (inclusive of USA).
Learning OBJECTIVES
After completing this educational activity, participants should be able to:
- Explain the concept of disease modification in the context of Crohn's disease.
- List well-defined disease modification outcomes used in other therapeutic areas and identify tools relevant to disease modification in Crohn's disease.
- List key therapeutic goals in patients with Crohn's disease particularly regarding disease impact on patients’ lives, mid-term and long-term complications.
- Outline the importance of red flags and risk stratification in primary care and specialist services.
- Identify tools which may be incorporated into establishing disease modification outcomes.
- Discuss how monitoring symptoms and inflammation biomarkers leads to superior patient/disease outcomes.
FACULTY
TIM RAINE
MD, PhD
Addenbrooke’s Hospital Cambridge,
UK.
RYAN UNGARO
MD, MS
Icahn School of Medicine at Mount Sinai New York, USA.
SÉVERINE VERMEIRE
MD, PhD
University Hospitals Leuven Leuven,
Belgium.
Disclosure STATEMENT
This independent medical education program has been supported and funded by Takeda. Takeda has provided funding for speaker fees and organizational costs.
The views and opinions expressed in this webinar belong solely to the authors. The contents of this webinar do not constitute an endorsement of the use of any product by Takeda or necessarily represent the views of Takeda.
The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Please note that products may have different product labeling according to geographical location.
All characters and events depicted in this activity are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental.
Financial Disclosures
Tim Raine, MD, PhD has disclosed the following financial relationships: Research/educational grants and/or speaker/consultation fees: AbbVie, Arena, Aslan, AstraZeneca, Boehringer Ingelheim, BMS, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Pfizer, Roche, Takeda, UCB.
Ryan Ungaro, MD, MS has disclosed the following financial relationships: Consultant and/or Speaker: AbbVie, BMS, Janssen, Pfizer, Takeda. Research grant: AbbVie, BMS. Grant reviewer: Pfizer.
Séverine Vermeire, MD, PhD has disclosed the following financial relationships: Grant/consulting and/or speaker fee: AbbVie, Galapagos, J&J, Pfizer, Takeda. Consulting and/or speaker fee: AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cytoki Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Imidomics, Janssen, J&J, Lilly, MiroBio, Morphic, MrMHealth, Pfizer, Progenity, Prometheus, Shire, Surrozen, Takeda, Theravance, Zealand Pharma.